Price target raised on Eli Lilly as obesity-drug boom rolls on
CNBC · RSS · · AI-summarised by FinFlash
Eli Lilly's price target has been raised, with analysts pointing to continued momentum in Mounjaro and Zepbound and further growth expected ahead. The call reflects sustained demand across the company's obesity and diabetes franchises. For investors, the upgrade signals confidence that Lilly's earnings trajectory can keep expanding rather than plateauing.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.